Safety and tolerability of monoclonal antibodies targeting the CGRP pathway and gepants in migraine prevention: A systematic review and network meta-analysis.
PAPERS | February 11-17, 2023 | |
Source: Cephalalgia 2023 Mar; 43(3). doi: 10.1177/03331024231152169Authors: Messina R, Huessler EM, Puledda F, Haghdoost F, Lebedeva ER, Diener HC
Direct comparisons of the tolerability and safety of migraine preventive treatments targeting the calcitonin gene-related peptide pathway are lacking. This study aimed to compare the safety and tolerability of anti-calcitonin gene-related peptide monoclonal antibodies and gepants in migraine prevention.
Pubmed ID: https://pubmed.ncbi.nlm.nih.gov/36786548/